Clinical Trial Search

Primary: Objective Response Rate as Measured by RECIST Criteria — 3; 6 participants

Primary: To Evaluate the Overall Response Rate (Complete Plus Partial Responses by RECIST Criteria) to the Combination of Paclitaxel Poliglumex and Pemetrexed as Therapy in…

Primary: Apathy Symptoms — -2.05; -1.95 units on a scale — p=0.55

Primary: Progression-free Survival (PFS) at 4 Months — 75 percentage of patients

Primary: Percentage of Participants With Response Determined by Change in Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples Before and After Treatment…

Primary: Mean Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Treatment — 3; 8.9; 7.6; 10.5 Points on a Scale

Primary: The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups. — 11.4; 5.9 Scores on a scale

Primary: Response to Sunitinib Therapy — 13 participants

Primary: Clinical Complete Response Rate at the Primary Tumor — 16 participants

Primary: Sustained Virologic Response (HCV RNA Below Lower Limit of Detection) — 32; 13; 43; 24 participants

Primary: Sustained Virologic Response (HCV RNA Below Lower Limit of Detection) — 3; 0; 39; 22 participants

Primary: AUC(0-t): Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (the Final Time With a Concentration ≥ LOQ) — 2650.1612; 661.9490 nmol.h/mL — p=<0.001

Primary: Complete Remission (CR) Rate — 11 percentage of participants

Primary: Overall Response Rate (ORR) — 9; 3; 6 participants

Primary: Maximum Plasma Concentration of Zalutumumab After Fourth Infusion — 104.3; 258.1; 494.3 mg/L